UBA1 drives cell cycle to promote malignancy and serves as a therapeutic target in Ewing Sarcoma

Shangjiang Yu, Runyi Jiang, Lei Zhou, Anshun Wu, Haifeng Wei, Shaohui He, Jianru Xiao · 2026

Read UBA1 drives cell cycle to promote malignancy and serves as a therapeutic target in Ewing Sarcoma by Shangjiang Yu, Runyi Jiang, Lei Zhou, Anshun Wu, Haifeng Wei, Shaohui He, Jianru Xiao (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13637259.txt.

Description

A protein that switches on the cell's protein-recycling machinery is proposed as a drug target in Ewing sarcoma by Yu and colleagues. Ewing sarcoma, an aggressive bone cancer that strikes mainly children and adolescents, often spreads early and resists current treatment, so new targets are urgently needed. The team found that UBA1, the first enzyme in the ubiquitin tagging pathway, was raised in tumour tissue and linked to worse prognosis, then tested what happens when it is blocked.

Silencing UBA1 slowed growth, colony formation, movement, and invasion in cell lines, while triggering arrest at a key cell-cycle checkpoint and cutting DNA synthesis. In mice, UBA1 depletion shrank tumours, and the inhibitor TAK-243 reproduced the cell-culture effects. Yu and colleagues conclude that blocking UBA1 disrupts the cell cycle in Ewing sarcoma, making it a promising therapeutic avenue worth pursuing in further studies.

Catalog record

CREATORShangjiang Yu, Runyi Jiang, Lei Zhou, Anshun Wu, Haifeng Wei, Shaohui He, Jianru Xiao
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE33 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13637259

Browse the full library · About the Tower of Babel